Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Innate Pharma    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
11/18/2020 11/19/2020 11/20/2020 11/23/2020 11/24/2020 Date
4.3(c) 4.16(c) 4.21(c) 4.24(c) 4.364 Last
1 407 209 668 057 516 153 494 210 320 448 Volume
+9.25% -3.26% +1.20% +0.71% +2.92% Change
More quotes
Financials
Sales 2020 88,8 M 106 M 106 M
Net income 2020 -29,9 M -35,5 M -35,5 M
Net cash position 2020 109 M 129 M 129 M
P/E ratio 2020 -5,01x
Yield 2020 -
Sales 2021 66,5 M 79,0 M 79,0 M
Net income 2021 -69,8 M -83,0 M -83,0 M
Net cash position 2021 15,7 M 18,7 M 18,7 M
P/E ratio 2021 -3,26x
Yield 2021 -
Capitalization 335 M 396 M 398 M
EV / Sales 2020 2,54x
EV / Sales 2021 4,80x
Nbr of Employees 247
Free-Float 77,3%
More Financials
Company
Innate Pharma specializes in the research and development of immunological-based drugs for cancers and infectious diseases treatment. The drug candidates belong to a new therapeutic class and are monoclonal antibodies targeting mechanisms of regulation of a particular compartment in our immune system: the innate immunity. This approach receives validating partnerships with 2 main players of the biopharmacy:... 
More about the company
Notations Surperformance© of Innate Pharma
Trading Rating : Investor Rating :
More Ratings
All news about INNATE PHARMA
11/18INNATE PHARMA : reports third quarter 2020 financial results and business update
AQ
11/17INNATE PHARMA : Revenue for Q3
PU
11/17INNATE PHARMA : reports third quarter 2020 financial results and business update
PU
11/17INNATE PHARMA : Reports Third Quarter 2020 Financial Results and Business Update
AQ
11/17INNATE PHARMA : reports third quarter 2020 financial results and business update
AQ
11/17Innate Pharma Reports Third Quarter 2020 Financial Results and Business Updat..
GL
11/17INNATE PHARMA : reports third quarter 2020 financial results and business update
GL
11/17INNATE PHARMA : 3rd quarter results
CO
11/16INNATE PHARMA : receives PRIME designation from the European Medicines Agency fo..
AQ
11/13INNATE PHARMA : to participate in upcoming investor conferences
AQ
11/13INNATE PHARMA : Receives Prime Designation From the European Medicines Agency fo..
AQ
11/13INNATE PHARMA : Receives prime designation from the european medicines agency fo..
GL
11/13INNATE PHARMA : Receives prime designation from the european medicines agency fo..
AQ
11/13Innate Pharma Receives Prime Designation From the European Medicines Agency f..
GL
11/12INNATE PHARMA : to Participate in upcoming investor conferences
AQ
More news
News in other languages on INNATE PHARMA
03:03a"Je n'ai pas perdu, mais…"
03:00aSTOCK MARKET PARIS : Les valeurs à suivre à Paris et en Europe
02:00aAVIS D'ANALYSTES DU JOUR : Aston Martin, Idorsia, Innate, Kering, LVMH, Natixis,..
11/17INNATE PHARMA : la trésorerie atteint 163,6 millions d'euros au 30 septembre
11/17Alors, on rebat les cartes ?
More news
Analyst Recommendations on INNATE PHARMA
More recommendations
Chart INNATE PHARMA
Duration : Period :
Innate Pharma Technical Analysis Chart | IPH | FR0010331421 | MarketScreener
Technical analysis trends INNATE PHARMA
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 7,98 €
Last Close Price 4,24 €
Spread / Highest target 159%
Spread / Average Target 88,1%
Spread / Lowest Target -5,66%
EPS Revisions
Managers
NameTitle
Mondher Mahjoubi Chairman-Executive Board & Chief Executive Officer
Hervé Eloi Dominique Brailly Chairman-Supervisory Board
Laure-Hélène Mercier CFO & Member-Executive Board
Eric Vivier Chief Scientific Officer & Senior Vice President
Odile Belzunce Senior VP-Compliance & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
INNATE PHARMA-28.86%396
LONZA GROUP AG61.38%46 348
MODERNA, INC.416.51%39 979
CELLTRION, INC.66.30%36 064
IQVIA HOLDINGS INC.10.39%32 701
SEAGEN INC.47.09%30 304